Evidence map›Paper›PMID 35673583›Full record

ArticleTheranostics2022

Image-guided drug delivery of nanotheranostics for targeted lung cancer therapy.

Xiaoran Yin, Yanan Cui, Richard S Kim, Wesley R Stiles, Seung Hun Park, Haoran Wang, Li Ma, Lin Chen, Yoonji Baek, Satoshi Kashiwagi and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Xiaoran YinDepartment of Oncology, The Second Affiliate Hospital of Xi'an Jiaotong University; Xi'an, Shaanxi, 710004, China.
Yanan CuiGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School; Boston, MA 02114, USA.
Richard S KimGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School; Boston, MA 02114, USA.
Wesley R StilesGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School; Boston, MA 02114, USA.
Seung Hun ParkGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School; Boston, MA 02114, USA.
Haoran WangGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School; Boston, MA 02114, USA.
Li MaDepartment of Pathology, The Second Affiliate Hospital of Xi'an Jiaotong University; Xi'an, Shaanxi, 710004, China.
Lin ChenDepartment of Pathology, Shaanxi Province People's Hospital, Xi'an; Shaanxi, 710068, China.
Yoonji BaekGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School; Boston, MA 02114, USA.
Satoshi KashiwagiGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School; Boston, MA 02114, USA.
Kai BaoGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School; Boston, MA 02114, USA.
Amy UlumbenGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School; Boston, MA 02114, USA.
Takeshi FukudaGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School; Boston, MA 02114, USA.
Homan KangGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School; Boston, MA 02114, USA.
Hak Soo ChoiGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School; Boston, MA 02114, USA.
Gordon Center for Medical Imaging · USSecond Affiliated Hospital of Xi'an Jiaotong University · CNShanxi Medical University · CN

Funding

Image-Guided Drug Delivery for Pancreatic Neuroendocrine Tumor.R01EB022230 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI CHOI, HAK SOO, HENARY, MAGED M · 2017 to 2020
$3.6M
Nanochelation Therapies for Iron Overload DisordersR01HL143020 · NHLBI · UNIVERSITY OF MASSACHUSETTS LOWELL · PI CHOI, HAK SOO, KIM, JONGHAN · 2018 to 2021
$2.6M
NHLBI NIH HHS R01 HL143020NIBIB NIH HHS R01 EB022230
6 · The paper itself

Abstract

Enormous efforts have been made to integrate various therapeutic interventions into multifunctional nanoplatforms, resulting in the advance of nanomedicine. Image-guided drug delivery plays a pivotal role in this field by providing specific targeting as well as image navigation for disease prognosis.

Indexed as

Antineoplastic AgentsLung NeoplasmsNanoparticlesDrug Delivery SystemsHumansTheranostic NanomedicineTissue DistributionAntineoplastic AgentsCancer therapyCombination therapyImage-guided surgeryRenal clearanceTheranostics

Identifiers

PMID35673583
PMCPMC9169367
OpenAlexW4285302698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.